AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019

March 19, 2019

SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the details of a poster presentation to be held at the American Association for Cancer Research (AACR) Annual Meeting 2019, taking place in Atlanta, Georgia. The poster session will be held on Tuesday April 2, 2019.

Details of the presentation are as follows:

Title: THOR-707, A Novel Not-alpha IL-2, Elicits Durable Pharmacodynamic Responses in Non-human Primates and Efficacy as Single Agent and in Combination with Anti PD-1 in Multiple Syngeneic Mouse ModelsPresenter: Ingrid B. Joseph, PhDSession Date: Tuesday, April 2, 2019 Time: 8:00 AM to 12:00 PM Eastern TimeLocation: Georgia World Congress Center, Exhibit Hall B, Poster Section 25

A copy of the poster will be available during the presentation in the Investors & Media section of the company’s website at https://www.synthorx.com, and will be archived and available at that site.

About Synthorx Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins™. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute. The company is headquartered in La Jolla, Calif.

Forward-Looking Statements This press release contains forward-looking statements about Synthorx as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, preclinical data or plans underlying THOR-707 and the development of Synthorx’s product candidates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as a development stage company; Synthorx’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in Synthorx’s plans to develop and commercialize its product candidates; the potential for any future clinical trials of THOR-707 or other product candidates to differ from preliminary or expected results; Synthorx’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Synthorx’s reliance on key third parties, including contract manufacturers and contract research organizations; Synthorx’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which Synthorx operates; and market conditions. These forward-looking statements are made as of the date of this press release, and Synthorx assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the documents the company files with the SEC available at www.sec.gov.

Investor Contacts: Enoch Kariuki, Pharm.D.Synthorx, Inc. ekariuki@synthorx.com 858-750-4750

Christina TartagliaStern Investor Relations christina.tartaglia@sternir.com 212-362-1200

Media Relations Contact:Lauren FishCanale Communications lauren@canalecomm.com 619-849-5386